How to Improve Chondrosarcoma Treatment? From Fundamental Research to Biomarker Discovery and Clinical Applications

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 December 2023) | Viewed by 3394

Special Issue Editor


E-Mail Website
Guest Editor
UMR6252 CIMAP—Centre de Recherche sur les Ions, les MAtériaux et la Photonique Team ARIA, Applications in Radiobiology with Accelerated Ions Campus Jules Horowitz, Bd Henri Becquerel, BP 55027, CEDEX 05, F-14076 Caen, France
Interests: cancer cell biology; chondrosarcoma; DNA damage response; signaling transduction; radiation-induced bystander effects; tumor cell radiosensitization; proteomics; radiation response biomarkers; radioresistance; tumor microenvironment; inflammatory
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Chondrosarcomas belong to a heterogeneous group of tumors that produce a cartilaginous matrix, and are the second most common bone disease in humans, representing 25% of bone neoplasms. Chondrosarcomas are historically classified as conventional (85%), and can be classified as central or peripheral. Most uncommon chondrosarcomas involving low- and middle-grade tumors develop slowly, with low metastatic potential. However, 5–10% of chondrosarcomas are advanced, and these includes mesenchymal and dedifferentiated chondrosarcomas as well as a subset of normal chondrosarcomas that has high metastatic prognosis and carries a bad prognosis.Clinical research on chondrosarcomas focuses on new noninvasive treatments and chemotherapy–refractory or metastatic chondrosarcomas. Although many types of cancer have many novel treatment options, chondrosarcomas have no effective treatment without surgery and continue to be associated with adverse clinical outcomes.

Recent research has suggested a few promising biomarkers and therapeutic targets for chondrosarcomas. Several molecular-targeting agents and innovative therapies have shown good antitumor activity in clinical studies in patients with advanced chondrosarcomas.

The main topics of this Special Issue are related to the latest basic studies on biomarkers and molecular targets, as well as the most recent clinical studies on the treatment of chondrosarcomas.

I am pleased to invite you to contribute to this Special Issue with research papers, up-to-date review articles, and commentaries.

Dr. François Chevalier
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chondrosarcoma
  • biomarkers
  • innovative therapy
  • therapeutic target
  • clinical studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 1056 KiB  
Review
Chondrosarcoma Resistance to Radiation Therapy: Origins and Potential Therapeutic Solutions
by Antoine Gilbert, Mihaela Tudor, Juliette Montanari, Kevin Commenchail, Diana Iulia Savu, Paul Lesueur and François Chevalier
Cancers 2023, 15(7), 1962; https://doi.org/10.3390/cancers15071962 - 24 Mar 2023
Cited by 17 | Viewed by 2821
Abstract
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which [...] Read more.
Chondrosarcoma is a malignant cartilaginous tumor that is particularly chemoresistant and radioresistant to X-rays. The first line of treatment is surgery, though this is almost impossible in some specific locations. Such resistances can be explained by the particular composition of the tumor, which develops within a dense cartilaginous matrix, producing a resistant area where the oxygen tension is very low. This microenvironment forces the cells to adapt and dedifferentiate into cancer stem cells, which are described to be more resistant to conventional treatments. One of the main avenues considered to treat this type of tumor is hadrontherapy, in particular for its ballistic properties but also its greater biological effectiveness against tumor cells. In this review, we describe the different forms of chondrosarcoma resistance and how hadrontherapy, combined with other treatments involving targeted inhibitors, could help to better treat high-grade chondrosarcoma. Full article
Show Figures

Figure 1

Back to TopTop